血管紧张素受体阻滞剂与阿尔茨海默病风险：一项荟萃分析。
Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis.
作者信息
Oscanoa Teodoro J, Amado José, Vidal Xavier, Romero-Ortuno Roman
机构信息
Centro de Investigacion de Seguridad de Medicamentos de la Facultad de Medicina Humana de la Universidad de San Martin de Porres (FMH-USMP), Lima, Peru.
Clinical Pharmacology Department, Valld'Hebron Hospital, Barcelona, Spain.
出版信息
Curr Rev Clin Exp Pharmacol. 2021;16(1):73-78. doi: 10.2174/1574884715666200131120224.
BACKGROUND
Anti-hypertensive medications may reduce the incidence of cognitive disorders. This may be due to reasons beyond their pure hypotensive effect. This study aimed to systematically review the association between the use of Angiotensin-Receptor Blockers (ARBs) and the incidence of Alzheimer's disease (AD).
METHODS
We systematically searched studies reporting the association between ARB use and the incidence of AD.
RESULTS
Ten studies (1 RCT, 2 case-control and 7 cohort studies) met the inclusion criteria. When all observational studies (9) were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.72, 95% CI: 0.58-0.88, p<0.001). In the only RCT, decrease in the incidence of AD was also significant (HR= 0.31, 95% CI: 0.14-0.68).
CONCLUSION
ARB use may reduce the risk of incident AD. This association does not imply causation and further research is required to clarify potential mechanisms.
背景
抗高血压药物可能会降低认知障碍的发生率。这可能是由于其单纯降压作用之外的原因。本研究旨在系统评价血管紧张素受体阻滞剂（ARB）的使用与阿尔茨海默病（AD）发病率之间的关联。
方法
我们系统检索了报告ARB使用与AD发病率之间关联的研究。
结果
10项研究（1项随机对照试验、2项病例对照研究和7项队列研究）符合纳入标准。当分析所有观察性研究（9项）时，使用ARB与AD发病风险降低相关（风险比0.72，95%置信区间：0.58 - 0.88，p<0.001）。在唯一的随机对照试验中，AD发病率的降低也具有显著性（风险比 = 0.31，95%置信区间：0.14 - 0.68）。
结论
使用ARB可能会降低AD发病风险。这种关联并不意味着因果关系，需要进一步研究以阐明潜在机制。
Zotero 插件